Sareum Holdings plc (LON:SAR – Get Free Report) was down 11.1% during trading on Tuesday . The company traded as low as GBX 40 ($0.51) and last traded at GBX 40 ($0.51). Approximately 670,878 shares changed hands during mid-day trading, a decline of 33% from the average daily volume of 1,000,678 shares. The stock had previously closed at GBX 45 ($0.57).
Sareum Trading Up 5.6 %
The firm has a market capitalization of £41.61 million, a PE ratio of -608.33 and a beta of -1.03. The business has a 50-day moving average of GBX 35.39 and a 200 day moving average of GBX 36.52.
About Sareum
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Read More
- Five stocks we like better than Sareum
- 3 Ways To Invest In Coffee, Other Than Drinking It
- AbbVie Stock: A Perfect Dip for Investors to Buy
- How is Compound Interest Calculated?
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What is a buyback in stocks? A comprehensive guide for investors
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
